





RMS TREATMENT THAT FITS YOUR SCHEDULE

Get relapsing and remitting multiple sclerosis (RMS) under control with KESIMPTA® (RMS). Someone from your health care team will give you guidance on how to take KESIMPTA with the Bensford® by first time.




Starter Dose Calendar

Pick a day and start with 1 dose a week for the first 3 weeks. Skip the 4th week.



1st Monthly Dose Calendar

Take your first monthly maintenance dose on the 5th week.



Maintenance Dose Calendar

Continue taking KESIMPTA once a month.

To keep it simple, try to take KESIMPTA on the same date every month. Example: If your first monthly dose is on April 15, take your next dose on May 15.

KESIMPTA was proven to significantly reduce the rates of relapses, and active lesions, and slow disability progression in 2 studies vs teriflunomide.

[See the results](#)



YOU DON'T HAVE TO GO IT ALONE

A KESIMPTA prescription comes with an **Alongside™** membership. We obsess about the details, so you don't have to.

What you get:

- A dedicated Coordinator—customized support from the same person every time you call
- \$0 Access Card—if eligible, get KESIMPTA for \$0 even if your insurance initially denies coverage*
- Helpful information and tools—membership materials, emails and other resources & supplies

[Get more with Alongside](#)

*Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to \$10,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at [start.kesimpta.com](#).

Patient Voices — Individual results may vary

“ KESIMPTA has worked well for me, and I have not had any relapses since starting. Also, KESIMPTA support and my dedicated Alongside coordinator have made a huge difference in my experience with having real people there to help you.”

- Jennie B. has taken KESIMPTA and has been compensated for her time.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

- **Infections** can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.
- **HBV reactivation** can happen if you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.
- **Progressive multifocal leukoencephalopathy (PML)** is a serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.
- **Weakness** can occur after other medicines that weaken the immune system could increase your risk of getting infections.

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

- Have or think you have an infection including HBV or PML.
- Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.
- Have had a recent vaccination or are scheduled to receive any vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you started treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.
 - Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.
 - Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.
- Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.
- Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you are taking, including prescription medicines, vitamins, and herbal supplements.

How should I use KESIMPTA?

See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.

- Use KESIMPTA exactly as your HCP tells you to use it.
- Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.
- Inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.

KESIMPTA may cause serious side effects including:

- **Injection-related reactions** are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms:
 - Redness of the skin, swelling, itching, and pain or
 - that may happen when certain substances are released in your body; fever, headache, pain in the muscles, chills, and tiredness.
- **KESIMPTA antibodies** cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.

The most common side effects of KESIMPTA include:

- Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.
- Headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](#) , or call 1-800-FDA-1088.

Please see full [Prescribing Information](#) , including [Medication Guide](#) .

[Full Prescribing Information](#) | [Medication Guide](#)

To ensure proper delivery, please add [Novartis](#) to your email contacts.

[Unsubscribe From KESIMPTA Emails](#) | [Privacy Policy](#)



Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936-1080

If you have any questions concerning e-mail or marketing communications from Novartis Pharmaceuticals Corporation, please email [novartis@novartis.com](#) (1-888-669-6682), Monday-Friday, 8:30 AM-5:00 PM ET .

KESIMPTA, the KESIMPTA logo, and Sensoready are registered trademarks of Novartis AG.